The latest 2021 WHO classification of CNS tumor relies heavily on isocitrate dehydrogenase (IDH) mutation status given its considerable diagnostic and predictive values: for example, the presence of IDH mutation in gliomas is linked to more favorable prognosis. This evidence concerns the gene IDH1 and central nervous system cancer.